PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
15.19%
ROE 15-20% – Solid returns. Seth Klarman would confirm if these levels are consistent over time. Review historical ROE trends.
-724.25%
Negative ROA indicates net losses or excessive assets. Benjamin Graham would question viability or capital misallocation.
206.70%
ROCE above 25% – Excellent capital efficiency. Warren Buffett would verify if this stems from a sustainable competitive advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.